Press Release

HINGHAM, Mass. , June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a

HINGHAM, Mass. , June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock in a registered

The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission BRAINTREE, Mass. , June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc.

The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures BRAINTREE, Mass. , April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass.

The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application BRAINTREE, Mass. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY ® Endovascular Robotic Surgical System,

All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position BRAINTREE, Mass. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular

Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study BRAINTREE, Mass. , Jan. 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ®

BRAINTREE, Mass. , Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding preferred investment options